abstract: BACKGROUND: @entity2 after living donor hepatectomy (LDH) may endanger donor safety during removal of thoracic epidural catheter (TEC). The present study was conducted to evaluate the extent and duration of immediate @entity0 after LDH. MATERIALS AND METHODS: A retrospective analysis of perioperative record of LDH over three years was conducted after IRB approval. Variables such as age, gender, BMI, ASA classification, liver volume on CT scan, preoperative and postoperative INR, platelet count (PC) and ALT of each donor for five days was noted. In addition, duration of surgery, remnant as percentage total liver volume (Remnant%), @entity1 , day of peak in PC and INR were also noted. @entity2 was defined as being present if INR exceeded 1.5 or platelet count fell below 1 * 10 5 /mm 3 on any day. Data was analyzed using SPSS 20 for Windows. Between group comparison was made using the Student 't' test for continuous variables and chi square test for categorical variables. Univariate analysis was done. Multiple logistic regression analysis was used to find independent factor associated with @entity2 . RESULTS: Eighty four (84) donors had @entity2 on second day (mean INR 1.9    0.42). Low BMI, % of remnant liver and duration of surgery were independent predictors of @entity2 . Right lobe hepatectomy had more @entity2 than left lobe and low BMI was the only independent predictor. There was no correlation of @entity2 with age, gender, @entity1 , presence of epidural catheter, postoperative ALT or duration of hospital stay. High INR was the main contributor for @entity2 . CONCLUSIONS: @entity2 is seen after donor hepatectomy. We recommend removal of the epidural catheter after the fifth postoperative day when INR falls below 1.5.

title: XXXX after live related donor hepatectomy: Incidence, predictors and implications for safety of thoracic epidural catheter.

answer: @entity0


abstract: @entity2 SQR9 exhibited predominantly antagonistic activities against a broad range of soilborne pathogens. The fungi-induced SQR9 extracts possess stronger antifungal activities compared with SQR9 monoculture extracts. To investigate how SQR9 fine-tunes lipopeptides (LPs) and a siderophore bacillibactin production to control different fungal pathogens, LPs and bacillibactin production and transcription of the respective encoding genes in SQR9 were measured and compared with six different soilborne fungal pathogens. SQR9 altered its spectrum of antifungal compounds production responding to different fungal pathogen. @entity5 was the major LP produced when SQR9 was confronted with @entity0 . Fengycin contributed to the antagonistic activity against @entity4 kleb, @entity0 , @entity1 , and Phytophthora parasitica. Surfactin participated in the antagonistic process against @entity3 , Rhizoctonia solani, and @entity1 . Bacillibactin was up-regulated when SQR9 was confronted with all tested fungi. The reduction in antagonistic activities of three LP and bacillibactin deficient mutants of SQR9 when confronted with the six soilborne fungal pathogens provided further evidence of the contribution of LPs and bacillibactin in controlling fungal pathogens. These results provide a new understanding of specific cues in bacteria-fungi interactions and provide insights for agricultural applications.

title: Responses of beneficial XXXX SQR9 to different soilborne fungal pathogens through the alteration of antifungal compounds production.

answer: @entity2


abstract: UNASSIGNED: We investigated the expression of @entity4 ( @entity4 ) and @entity5 ( @entity5 ) in @entity0 . To analyze @entity4 and @entity5 expression, an endocervical cytobrush sample was taken for total RNA isolation. @entity5 and @entity4 mRNA was quantified from total RNA using quantitative reverse transcription-polymerase chain reaction. A total of 71 samples were collected and classified according to the Bethesda Classification of squamous @entity1 . @entity4 expression was observed in 9 (12.7%) samples; of these, 5.3, 5.9, 14.8, and 37.5% in the groups that were cytology negative for intraepithelial lesion or malignancy, @entity3 ( @entity3 ), @entity3 ( @entity3 ), and @entity2 , respectively. The expression level of @entity4 was significantly higher in the group with @entity2 as compared with the groups negative for intraepithelial lesion or malignancy, @entity3 , and @entity3 (P < 0.0005). @entity5 mRNA was expressed in all samples. @entity5 expression was significantly higher in @entity2 groups compared with @entity3 , @entity3 , and negative for intraepithelial lesion or malignancy groups. We found that @entity4 and @entity5 expressions in the @entity3 and @entity2 groups were higher than expression in cytological normal samples. Additional studies should be conducted to examine the function of transcription factors during different stages of the transformation of cervical @entity0 cells.

title: XXXX and @entity5 are overexpressed in @entity0 .

answer: @entity4


abstract: UNASSIGNED: We investigated the expression of @entity4 ( @entity4 ) and @entity5 ( @entity5 ) in @entity0 . To analyze @entity4 and @entity5 expression, an endocervical cytobrush sample was taken for total RNA isolation. @entity5 and @entity4 mRNA was quantified from total RNA using quantitative reverse transcription-polymerase chain reaction. A total of 71 samples were collected and classified according to the Bethesda Classification of squamous @entity1 . @entity4 expression was observed in 9 (12.7%) samples; of these, 5.3, 5.9, 14.8, and 37.5% in the groups that were cytology negative for intraepithelial lesion or malignancy, @entity3 ( @entity3 ), @entity3 ( @entity3 ), and @entity2 , respectively. The expression level of @entity4 was significantly higher in the group with @entity2 as compared with the groups negative for intraepithelial lesion or malignancy, @entity3 , and @entity3 (P < 0.0005). @entity5 mRNA was expressed in all samples. @entity5 expression was significantly higher in @entity2 groups compared with @entity3 , @entity3 , and negative for intraepithelial lesion or malignancy groups. We found that @entity4 and @entity5 expressions in the @entity3 and @entity2 groups were higher than expression in cytological normal samples. Additional studies should be conducted to examine the function of transcription factors during different stages of the transformation of cervical @entity0 cells.

title: @entity4 and @entity5 are overexpressed in XXXX .

answer: @entity0


abstract: UNASSIGNED: We investigated the expression of @entity4 ( @entity4 ) and @entity5 ( @entity5 ) in @entity0 . To analyze @entity4 and @entity5 expression, an endocervical cytobrush sample was taken for total RNA isolation. @entity5 and @entity4 mRNA was quantified from total RNA using quantitative reverse transcription-polymerase chain reaction. A total of 71 samples were collected and classified according to the Bethesda Classification of squamous @entity1 . @entity4 expression was observed in 9 (12.7%) samples; of these, 5.3, 5.9, 14.8, and 37.5% in the groups that were cytology negative for intraepithelial lesion or malignancy, @entity3 ( @entity3 ), @entity3 ( @entity3 ), and @entity2 , respectively. The expression level of @entity4 was significantly higher in the group with @entity2 as compared with the groups negative for intraepithelial lesion or malignancy, @entity3 , and @entity3 (P < 0.0005). @entity5 mRNA was expressed in all samples. @entity5 expression was significantly higher in @entity2 groups compared with @entity3 , @entity3 , and negative for intraepithelial lesion or malignancy groups. We found that @entity4 and @entity5 expressions in the @entity3 and @entity2 groups were higher than expression in cytological normal samples. Additional studies should be conducted to examine the function of transcription factors during different stages of the transformation of cervical @entity0 cells.

title: @entity4 and XXXX are overexpressed in @entity0 .

answer: @entity5


abstract: External ventricular drainage (EVD) is frequently used in neurosurgery to drain cerebrospinal fluid in @entity0 with @entity3 . We performed a retrospective single center study in order to evaluate the incidence of @entity1 and to identify underlying risk factors. 246 EVDs were placed in 218 @entity0 over a 30-month period. EVD was continued in median for 7 days (range 1-44). The cumulative incidence of @entity1 was 8.3% (95% CI, 5.3-12.7) with a device-associated @entity2 rate of 10.4 per 1000 drainage days (95% CI, 6.2-16.5). The pathogens most commonly identified were coagulase-negative Staphylococcus (62%) followed by Enterococcus spp. (19%). @entity0 with an EVD-related @entity2 had a significantly longer ICU (11 versus 21 days, P < 0.01) and hospital stay (20 versus 28.5 days, P < 0.01) than @entity0 without. Median total duration of external drainage was twice as long in @entity0 with EVD-related @entity2 (6 versus 12 days, P < 0.01). However, there was no significant difference in the duration between first EVD placement and the occurrence of EVD-related @entity2 and EVD removal in @entity0 without EVD-related @entity2 (6 versus 7 days, P = 0.87), respectively. Interestingly no risk factor for EVD-related @entity2 could be identified in our cohort of @entity0 .

title: XXXX : risk factors and outcome.

answer: @entity1


abstract: The treatment of @entity5 ( @entity5 ) usually involves surgical excision or stereotactic radiosurgery. However, for large @entity5 (mean diameter  >  3  cm), stereotactic radiosurgery is rarely used, leaving @entity0 with limited noninvasive treatment options. Recently, the use of fractionated stereotactic radiotherapy (FSRT) has been effective in treating small to medium-sized @entity5 . We present a @entity0 with a large @entity5 treated with FSRT. The @entity0 was a 43-year-old @entity0 presenting with imbalance, @entity3 , vertigo, and right-sided hearing decline associated with @entity2 and @entity4 . Magnetic resonance (MR) imaging revealed a large, 3.8-cm, @entity5 compressing the fourth ventricle. Following right frontal ventriculoperitoneal shunt placement, the @entity0 underwent FSRT for treatment of the @entity1 . Using the Radionics X-Knife 4.0 3D treatment planning system, a total of 54  Gy was delivered in 1.8-Gy daily fractions with the prescription isodose line of 90%. Treatments were delivered using a dedicated Varian 6/100 linear accelerator, and head immobilization was achieved with the Gill-Thomas-Cosman relocatable stereotactic frame. The @entity0 was subsequently evaluated with serial contrast-enhanced MR imaging. Following FSRT, local control (defined as the absence of @entity1 progression) was achieved, and treatment was well tolerated. There was no hearing-related, trigeminal, or facial-nerve morbidity following FSRT at 63-month follow-up. Treating a @entity0 with a large @entity5 with FSRT resulted in @entity1 control, with no trigeminal nerve, facial nerve, or hearing-related morbidity. These results support FSRT as a potential noninvasive treatment modality for @entity5 some would consider too large for single-fraction stereotactic radiosurgery (SRS).

title: The treatment of a large XXXX with fractionated stereotactic radiotherapy.

answer: @entity1


abstract: BACKGROUND: The aim of this study was to investigate the utility of diffusion weighted imaging (DWI) using Apparent Diffusion Coefficient (ADC) values in discriminating between @entity0 with @entity1 and normal prostate tissue before the initial systematic core biopsy. The relationship between histological grade of @entity3 and ADC values in the peripheral zone was also investigated. MATERIAL/METHODS: Our study included 62 @entity0 who underwent magnetic resonance imaging (MRI) of the pelvis. The examinations were performed in T1-, T2-weighted, DWI and T1 after dynamic contrast administration sequences. In all @entity0 there were abnormal foci within the peripheral zone determined in DWI/ADC. ADC values were compared with the Gleason score (GS) after core needle biopsy (CNB) in @entity0 with low, medium and high stage @entity1 . RESULTS: Within the examined group of @entity0 , ADC was statistically higher for normal tissue than for cancerous tissue (p=0.00). Mean ADC values for @entity0 with low, intermediate and high GS were 0.85  0.03, 0.72  0.03, and 0.61  0.04, respectively. CONCLUSIONS: DWI/ADC is useful in differentiating high-risk @entity0 from those at low and intermediate risk, since there is a significant correlation between ADC values determined in @entity0 included in three different groups according to their Gleason score. This information may be helpful in the assessment of @entity3 @entity2 .

title: The Utility of Diffusion Weighted Imaging (DWI) Using Apparent Diffusion Coefficient (ADC) Values in Discriminating Between XXXX and Normal Tissue.

answer: @entity3


abstract: UNASSIGNED: MicroRNA-143 serves as a @entity1 suppressor in many @entity0 @entity1 . However, its involvement in @entity2 ( @entity2 ) is still unclear. In this study, we investigated the effects of @entity3 in @entity2 tumorigenesis and development. Using real-time quantitative reverse transcription-polymerase chain reaction, we detected @entity3 expression in 109 pairs of @entity0 @entity2 and adjacent noncancerous tissues. The associations between @entity3 expression and clinicopathological factors and prognosis of @entity2 @entity0 were also statistically analyzed. Further, the effects of @entity3 on the biological behavior of @entity2 cells were investigated. @entity3 expression was significantly downregulated in @entity2 tissue samples and cell lines. Decreased @entity3 expression was significantly associated with advanced T classifications, positive N classification, advanced TNM stage, and shorter overall survival. In addition, upregulation of @entity3 in Tca8113 cells reduced cell proliferation, invasion, and migration, as well as promoted cell apoptosis in vitro. These findings validate the clinical significance of @entity3 in @entity2 and reveal that it may be an intrinsic regulator of @entity1 progression and a potential prognostic factor for this disease.

title: Decreased microRNA-143 expression and its @entity1 suppressive function in @entity0 XXXX .

answer: @entity2


abstract: UNASSIGNED: MicroRNA-143 serves as a @entity1 suppressor in many @entity0 @entity1 . However, its involvement in @entity2 ( @entity2 ) is still unclear. In this study, we investigated the effects of @entity3 in @entity2 tumorigenesis and development. Using real-time quantitative reverse transcription-polymerase chain reaction, we detected @entity3 expression in 109 pairs of @entity0 @entity2 and adjacent noncancerous tissues. The associations between @entity3 expression and clinicopathological factors and prognosis of @entity2 @entity0 were also statistically analyzed. Further, the effects of @entity3 on the biological behavior of @entity2 cells were investigated. @entity3 expression was significantly downregulated in @entity2 tissue samples and cell lines. Decreased @entity3 expression was significantly associated with advanced T classifications, positive N classification, advanced TNM stage, and shorter overall survival. In addition, upregulation of @entity3 in Tca8113 cells reduced cell proliferation, invasion, and migration, as well as promoted cell apoptosis in vitro. These findings validate the clinical significance of @entity3 in @entity2 and reveal that it may be an intrinsic regulator of @entity1 progression and a potential prognostic factor for this disease.

title: Decreased microRNA-143 expression and its XXXX suppressive function in @entity0 @entity2 .

answer: @entity1


abstract: UNASSIGNED: MicroRNA-143 serves as a @entity1 suppressor in many @entity0 @entity1 . However, its involvement in @entity2 ( @entity2 ) is still unclear. In this study, we investigated the effects of @entity3 in @entity2 tumorigenesis and development. Using real-time quantitative reverse transcription-polymerase chain reaction, we detected @entity3 expression in 109 pairs of @entity0 @entity2 and adjacent noncancerous tissues. The associations between @entity3 expression and clinicopathological factors and prognosis of @entity2 @entity0 were also statistically analyzed. Further, the effects of @entity3 on the biological behavior of @entity2 cells were investigated. @entity3 expression was significantly downregulated in @entity2 tissue samples and cell lines. Decreased @entity3 expression was significantly associated with advanced T classifications, positive N classification, advanced TNM stage, and shorter overall survival. In addition, upregulation of @entity3 in Tca8113 cells reduced cell proliferation, invasion, and migration, as well as promoted cell apoptosis in vitro. These findings validate the clinical significance of @entity3 in @entity2 and reveal that it may be an intrinsic regulator of @entity1 progression and a potential prognostic factor for this disease.

title: Decreased microRNA-143 expression and its @entity1 suppressive function in XXXX @entity2 .

answer: @entity0


abstract: INTRODUCTON: Treatment of @entity2 ( @entity2 ) requires a multidisciplinary approach that may involve medical oncologists, geneticists, genetic counsellors, and urologists. The objective of our survey was to obtain current and representative information about the use and perceived importance of genetic testing for @entity2 in Canada. METHODS: A self-administered web-based survey was provided to Canadian medical oncologists, geneticists, genetic counsellors, and urologists in collaboration with their respective associations. The survey was created through an iterative process in consultation with the @entity1 Research Network of Canada and contained both quantitative and qualitative components. The survey was designed to be exploratory and results were compared across regions. RESULTS: The overall response was low (6.6%). Of the respondents, 42%, 33%, 19%, 5% were genetic counsellors, urologists, medical oncologists and medical geneticists, respectively. Of the respondents, 62.7% described their practice as academic, and 37.3% described it as non-academic. Non-academic respondents tended to refer for genetic counselling less frequently than academic (48.6% vs. 67.2%). Most respondents believed that genetic testing for @entity2 was available (82.8%), although 47.7% did not know which tests were available. This observation was consistent across provinces. Testing for @entity0 was given the highest priority among respondents. Limited provider knowledge, clinical guidelines, institutional funding, access, and poor coordination between disciplines were cited as barriers to testing. INTERPRETATION: There is a need to increase provider knowledge of genetic testing for @entity2 . These findings support the development of practice guidelines and national strategies to improve coordination of specialists and access to genetics services. Limitations of the present study include low survey response which did not allow for inferential analysis by geographic region or respondent specialty.

title: Knowledge of genetic testing for XXXX in Canada is lacking: The results of the Canadian @entity1 needs assessment survey.

answer: @entity1


abstract: INTRODUCTON: Treatment of @entity2 ( @entity2 ) requires a multidisciplinary approach that may involve medical oncologists, geneticists, genetic counsellors, and urologists. The objective of our survey was to obtain current and representative information about the use and perceived importance of genetic testing for @entity2 in Canada. METHODS: A self-administered web-based survey was provided to Canadian medical oncologists, geneticists, genetic counsellors, and urologists in collaboration with their respective associations. The survey was created through an iterative process in consultation with the @entity1 Research Network of Canada and contained both quantitative and qualitative components. The survey was designed to be exploratory and results were compared across regions. RESULTS: The overall response was low (6.6%). Of the respondents, 42%, 33%, 19%, 5% were genetic counsellors, urologists, medical oncologists and medical geneticists, respectively. Of the respondents, 62.7% described their practice as academic, and 37.3% described it as non-academic. Non-academic respondents tended to refer for genetic counselling less frequently than academic (48.6% vs. 67.2%). Most respondents believed that genetic testing for @entity2 was available (82.8%), although 47.7% did not know which tests were available. This observation was consistent across provinces. Testing for @entity0 was given the highest priority among respondents. Limited provider knowledge, clinical guidelines, institutional funding, access, and poor coordination between disciplines were cited as barriers to testing. INTERPRETATION: There is a need to increase provider knowledge of genetic testing for @entity2 . These findings support the development of practice guidelines and national strategies to improve coordination of specialists and access to genetics services. Limitations of the present study include low survey response which did not allow for inferential analysis by geographic region or respondent specialty.

title: Knowledge of genetic testing for @entity1 in Canada is lacking: The results of the Canadian XXXX needs assessment survey.

answer: @entity1


abstract: UNASSIGNED: MicroRNAs (miRNAs) have been implicated in @entity2 ( @entity2 ) development and associated with prognostic indicators such as disease stage and survival. Prognostic associations are often based on few individuals and imprecise. In this study, we utilize population-based data from 1,141 @entity2 cases to replicate previously reported associations between 121 miRNAs and disease stage and survival. The Agilent @entity0 miRNA Microarray V19.0 was used to generate miRNA data following a stringent quality control protocol. Assessment of survival was done using Cox Proportional Hazard models adjusting for age, disease stage and @entity1 molecular phenotype. Five miRNAs were associated with more @entity4 stage; @entity5 -5p and hsa-miR-31-5p showed increased expression with more advanced @entity1 stage, while hsa-miR-200b-3p, @entity8 and hsa-miR-451a had decreased expression with more @entity1 . Thirteen miRNAs were associated with @entity2 mortality among individuals diagnosed with @entity3 while 14 were associated with @entity2 mortality after a diagnosis with @entity1 . Strongest associations were observed for those miRNAs that were expressed in a small subset of @entity1 . Most notable associations were for @entity5 -3p [hazard ratio (HR) 2.94, 95% confidence interval (CI) 1.54, 5.61], and @entity6 (HR 10.28, 95% CI 1.31, 80.84) with @entity3 and @entity7 -5p (HR 0.17, 95% CI 0.05, 0.54) for @entity1 . hsa-miR-374a-5p, @entity9 and hsa-miR-18a-5p significantly reduced the hazard of dying for all cases, regardless of @entity1 site. Our findings illustrate the need for a large sample to evaluate the association of miRNAs with survival and disease stage in order to determine associations by @entity1 site.

title: An evaluation and replication of miRNAs with disease stage and XXXX -specific mortality.

answer: @entity2


abstract: BACKGROUND: Primary @entity1 showing features of salivary gland-type @entity2 are extremely rare. METHODS: Eight @entity0 with primary @entity1 showing light microscopic and immunohistochemical features of salivary gland-type mixed @entity2 were studied. RESULTS: The @entity0 were six @entity0 and two @entity0 , ages 35-69 years (mean, 52.5 years). The @entity2 ranged from 2 to 16 cm in greatest diameter. In two @entity0 the lesions presented as polypoid endobronchial lesions obstructing the lumen; in another two @entity0 the lesions were found in close proximity or in continuity with a bronchus; in three @entity0 , the lesions presented as peripheral parenchymatous nodules unrelated to a bronchus; and in one @entity0 , the relationship to the bronchus could not be determined. Histologically, the lesions were biphasic, showing admixtures in varying proportions of epithelial elements containing a predominant myoepithelial cell population with a stromal component containing an abundant myxoid or focally chondroid matrix. Immunohistochemical studies showed strong positivity of the cells in the epithelial component with low molecular weight keratins (CAM 5.2), and to a lesser extent with broad spectrum keratin, actin, and @entity4 antibodies. The cells also showed variable reactivity in the epithelial and nonepithelial elements with S-100 protein and glial fibrillary acidic protein. Six @entity2 were grossly and histologically benign; in two @entity0 , the @entity2 were larger, locally invasive, and showed more atypical histologic features. All @entity0 were treated with surgical excision. On follow-up, of the six @entity0 with histologically benign-appearing @entity2 , one was alive and well 6 years after surgery; another died 4 years after surgery of a second unrelated @entity2 ; one died during the immediate postoperative period of @entity3 ; and three have been lost to follow-up. In the two @entity0 with histologically atypical lesions, the @entity2 recurred and metastasized after 2 and 3 years, respectively, with one of them leading to death caused by widespread metastases and superior @entity5 . CONCLUSIONS: Review of the literature and the findings in the current series indicate that salivary gland-type mixed @entity2 of the lung may present with a spectrum of histologic features and clinical behavior, ranging from benign to frankly malignant, similar to that observed for their salivary gland counterparts. Size of the lesion at the time of presentation, extent of local infiltration, and degree of mitotic activity appear to be the most reliable prognostic features of these @entity2 .

title: Benign and malignant salivary gland-type mixed XXXX of the lung. Clinicopathologic and immunohistochemical study of eight cases.

answer: @entity2


abstract: Six @entity0 with @entity2 ( @entity2 ) expressing @entity3 antigen ( @entity3 + @entity2 ) were studied. They consisted of five @entity0 with M1 and one with an M2 morphology. Two cases expressed other lymphoid-associated antigens, in addition to @entity3 . The complete remission rate was 50%. One @entity0 had central nervous system recurrence. Cytogenetic analysis demonstrated normal karyotypes in all the cases. All but one had germline configurations of the T-cell receptor (TCR) genes and @entity4 gene. However, all did not have detectable recombinase activating gene-1 activity by the RT-PCR technique. We performed colony formation assay in two @entity0 , and no enhancement of colony formation by @entity1 was noted. The results presented here, together with those reported previously, suggest that @entity3 + @entity2 may demonstrate lineage infidelity.

title: Clinical and biologic characteristics of @entity3 + XXXX . Our experience and literature review.

answer: @entity2


abstract: Six @entity0 with @entity2 ( @entity2 ) expressing @entity3 antigen ( @entity3 + @entity2 ) were studied. They consisted of five @entity0 with M1 and one with an M2 morphology. Two cases expressed other lymphoid-associated antigens, in addition to @entity3 . The complete remission rate was 50%. One @entity0 had central nervous system recurrence. Cytogenetic analysis demonstrated normal karyotypes in all the cases. All but one had germline configurations of the T-cell receptor (TCR) genes and @entity4 gene. However, all did not have detectable recombinase activating gene-1 activity by the RT-PCR technique. We performed colony formation assay in two @entity0 , and no enhancement of colony formation by @entity1 was noted. The results presented here, together with those reported previously, suggest that @entity3 + @entity2 may demonstrate lineage infidelity.

title: Clinical and biologic characteristics of XXXX + @entity2 . Our experience and literature review.

answer: @entity3


abstract: UNASSIGNED: Newer oral @entity7 inhibitors are more potent and have faster onset of action than @entity6 . However, the efficacy and safety in @entity0 with non-ST-elevation @entity5 (NSTE-ACS) are not well studied. A systemic search of MEDLINE and EMBASE databases was performed to identify randomized clinical trials comparing newer oral @entity7 inhibitors ( @entity8 or @entity9 ) to @entity6 in @entity0 with NSTE-ACS. The primary outcome was a composite of @entity2 , @entity4 ( @entity4 ), and @entity1 (major cardiovascular events [MACE]). Secondary outcomes were individual components of the primary outcome, all-cause mortality, and Thrombolysis In @entity4 (TIMI) major and @entity3 . A total of 31,470 @entity0 with NSTE-ACS from 4 randomized clinical trials were included (newer oral @entity7 inhibitors: 15,951; @entity6 : 15,519). Newer oral @entity7 inhibitors significantly decreased MACE (relative risk [RR] 0.87, 95% confidence interval [CI] 0.80 to 0.95) and @entity4 (RR 0.85, 95% CI 0.75 to 0.96) and showed a trend toward reduction of @entity2 (RR 0.89, 95% CI 0.71 to 1.01). There was a significant increase in TIMI major @entity3 (RR 1.27, 95% CI 1.07 to 1.50) and TIMI major or @entity3 (RR 1.20, 95% CI 1.02 to 1.42). Results were largely similar when stratified by @entity9 versus @entity8 (pinteraction >0.05) except for increased TIMI major/ @entity3 with @entity8 than @entity9 (pinteraction  = 0.01). In conclusion, in @entity0 with NSTE-ACS, newer oral @entity7 inhibitors decrease MACE and @entity4 at the expense of a significant increase in the risk of @entity3 . Treatment of 1,000 @entity0 with newer oral @entity7 inhibitors will prevent 16 MACE and 13 MIs at the expense of increase in 6 major @entity3 events.

title: Meta-Analysis of Comparison of the Newer Oral @entity7 Inhibitors ( XXXX or @entity9 ) to @entity6 in @entity0 With Non-ST-Elevation Acute Coronary Syndrome.

answer: @entity8


abstract: UNASSIGNED: Newer oral @entity7 inhibitors are more potent and have faster onset of action than @entity6 . However, the efficacy and safety in @entity0 with non-ST-elevation @entity5 (NSTE-ACS) are not well studied. A systemic search of MEDLINE and EMBASE databases was performed to identify randomized clinical trials comparing newer oral @entity7 inhibitors ( @entity8 or @entity9 ) to @entity6 in @entity0 with NSTE-ACS. The primary outcome was a composite of @entity2 , @entity4 ( @entity4 ), and @entity1 (major cardiovascular events [MACE]). Secondary outcomes were individual components of the primary outcome, all-cause mortality, and Thrombolysis In @entity4 (TIMI) major and @entity3 . A total of 31,470 @entity0 with NSTE-ACS from 4 randomized clinical trials were included (newer oral @entity7 inhibitors: 15,951; @entity6 : 15,519). Newer oral @entity7 inhibitors significantly decreased MACE (relative risk [RR] 0.87, 95% confidence interval [CI] 0.80 to 0.95) and @entity4 (RR 0.85, 95% CI 0.75 to 0.96) and showed a trend toward reduction of @entity2 (RR 0.89, 95% CI 0.71 to 1.01). There was a significant increase in TIMI major @entity3 (RR 1.27, 95% CI 1.07 to 1.50) and TIMI major or @entity3 (RR 1.20, 95% CI 1.02 to 1.42). Results were largely similar when stratified by @entity9 versus @entity8 (pinteraction >0.05) except for increased TIMI major/ @entity3 with @entity8 than @entity9 (pinteraction  = 0.01). In conclusion, in @entity0 with NSTE-ACS, newer oral @entity7 inhibitors decrease MACE and @entity4 at the expense of a significant increase in the risk of @entity3 . Treatment of 1,000 @entity0 with newer oral @entity7 inhibitors will prevent 16 MACE and 13 MIs at the expense of increase in 6 major @entity3 events.

title: Meta-Analysis of Comparison of the Newer Oral XXXX Inhibitors ( @entity8 or @entity9 ) to @entity6 in @entity0 With Non-ST-Elevation Acute Coronary Syndrome.

answer: @entity7


abstract: UNASSIGNED: Newer oral @entity7 inhibitors are more potent and have faster onset of action than @entity6 . However, the efficacy and safety in @entity0 with non-ST-elevation @entity5 (NSTE-ACS) are not well studied. A systemic search of MEDLINE and EMBASE databases was performed to identify randomized clinical trials comparing newer oral @entity7 inhibitors ( @entity8 or @entity9 ) to @entity6 in @entity0 with NSTE-ACS. The primary outcome was a composite of @entity2 , @entity4 ( @entity4 ), and @entity1 (major cardiovascular events [MACE]). Secondary outcomes were individual components of the primary outcome, all-cause mortality, and Thrombolysis In @entity4 (TIMI) major and @entity3 . A total of 31,470 @entity0 with NSTE-ACS from 4 randomized clinical trials were included (newer oral @entity7 inhibitors: 15,951; @entity6 : 15,519). Newer oral @entity7 inhibitors significantly decreased MACE (relative risk [RR] 0.87, 95% confidence interval [CI] 0.80 to 0.95) and @entity4 (RR 0.85, 95% CI 0.75 to 0.96) and showed a trend toward reduction of @entity2 (RR 0.89, 95% CI 0.71 to 1.01). There was a significant increase in TIMI major @entity3 (RR 1.27, 95% CI 1.07 to 1.50) and TIMI major or @entity3 (RR 1.20, 95% CI 1.02 to 1.42). Results were largely similar when stratified by @entity9 versus @entity8 (pinteraction >0.05) except for increased TIMI major/ @entity3 with @entity8 than @entity9 (pinteraction  = 0.01). In conclusion, in @entity0 with NSTE-ACS, newer oral @entity7 inhibitors decrease MACE and @entity4 at the expense of a significant increase in the risk of @entity3 . Treatment of 1,000 @entity0 with newer oral @entity7 inhibitors will prevent 16 MACE and 13 MIs at the expense of increase in 6 major @entity3 events.

title: Meta-Analysis of Comparison of the Newer Oral @entity7 Inhibitors ( @entity8 or XXXX ) to @entity6 in @entity0 With Non-ST-Elevation Acute Coronary Syndrome.

answer: @entity9


abstract: UNASSIGNED: Newer oral @entity7 inhibitors are more potent and have faster onset of action than @entity6 . However, the efficacy and safety in @entity0 with non-ST-elevation @entity5 (NSTE-ACS) are not well studied. A systemic search of MEDLINE and EMBASE databases was performed to identify randomized clinical trials comparing newer oral @entity7 inhibitors ( @entity8 or @entity9 ) to @entity6 in @entity0 with NSTE-ACS. The primary outcome was a composite of @entity2 , @entity4 ( @entity4 ), and @entity1 (major cardiovascular events [MACE]). Secondary outcomes were individual components of the primary outcome, all-cause mortality, and Thrombolysis In @entity4 (TIMI) major and @entity3 . A total of 31,470 @entity0 with NSTE-ACS from 4 randomized clinical trials were included (newer oral @entity7 inhibitors: 15,951; @entity6 : 15,519). Newer oral @entity7 inhibitors significantly decreased MACE (relative risk [RR] 0.87, 95% confidence interval [CI] 0.80 to 0.95) and @entity4 (RR 0.85, 95% CI 0.75 to 0.96) and showed a trend toward reduction of @entity2 (RR 0.89, 95% CI 0.71 to 1.01). There was a significant increase in TIMI major @entity3 (RR 1.27, 95% CI 1.07 to 1.50) and TIMI major or @entity3 (RR 1.20, 95% CI 1.02 to 1.42). Results were largely similar when stratified by @entity9 versus @entity8 (pinteraction >0.05) except for increased TIMI major/ @entity3 with @entity8 than @entity9 (pinteraction  = 0.01). In conclusion, in @entity0 with NSTE-ACS, newer oral @entity7 inhibitors decrease MACE and @entity4 at the expense of a significant increase in the risk of @entity3 . Treatment of 1,000 @entity0 with newer oral @entity7 inhibitors will prevent 16 MACE and 13 MIs at the expense of increase in 6 major @entity3 events.

title: Meta-Analysis of Comparison of the Newer Oral @entity7 Inhibitors ( @entity8 or @entity9 ) to XXXX in @entity0 With Non-ST-Elevation Acute Coronary Syndrome.

answer: @entity6


abstract: UNASSIGNED: Newer oral @entity7 inhibitors are more potent and have faster onset of action than @entity6 . However, the efficacy and safety in @entity0 with non-ST-elevation @entity5 (NSTE-ACS) are not well studied. A systemic search of MEDLINE and EMBASE databases was performed to identify randomized clinical trials comparing newer oral @entity7 inhibitors ( @entity8 or @entity9 ) to @entity6 in @entity0 with NSTE-ACS. The primary outcome was a composite of @entity2 , @entity4 ( @entity4 ), and @entity1 (major cardiovascular events [MACE]). Secondary outcomes were individual components of the primary outcome, all-cause mortality, and Thrombolysis In @entity4 (TIMI) major and @entity3 . A total of 31,470 @entity0 with NSTE-ACS from 4 randomized clinical trials were included (newer oral @entity7 inhibitors: 15,951; @entity6 : 15,519). Newer oral @entity7 inhibitors significantly decreased MACE (relative risk [RR] 0.87, 95% confidence interval [CI] 0.80 to 0.95) and @entity4 (RR 0.85, 95% CI 0.75 to 0.96) and showed a trend toward reduction of @entity2 (RR 0.89, 95% CI 0.71 to 1.01). There was a significant increase in TIMI major @entity3 (RR 1.27, 95% CI 1.07 to 1.50) and TIMI major or @entity3 (RR 1.20, 95% CI 1.02 to 1.42). Results were largely similar when stratified by @entity9 versus @entity8 (pinteraction >0.05) except for increased TIMI major/ @entity3 with @entity8 than @entity9 (pinteraction  = 0.01). In conclusion, in @entity0 with NSTE-ACS, newer oral @entity7 inhibitors decrease MACE and @entity4 at the expense of a significant increase in the risk of @entity3 . Treatment of 1,000 @entity0 with newer oral @entity7 inhibitors will prevent 16 MACE and 13 MIs at the expense of increase in 6 major @entity3 events.

title: Meta-Analysis of Comparison of the Newer Oral @entity7 Inhibitors ( @entity8 or @entity9 ) to @entity6 in XXXX With Non-ST-Elevation Acute Coronary Syndrome.

answer: @entity0


abstract: Purpose. Tailgut cysts with malignant transformation are rare entities. We discuss the diagnostic strategy and treatment of a @entity1 within a tailgut cyst. Methods. In this study we report on the case of a 61-year-old @entity0 with a @entity1 arising within a tailgut cyst and an overview of the literature emphasising the histopathological characteristics and differential diagnosis. Results. Our @entity0 presented with @entity3 , @entity2 , and increased urgency of defecation. MRI scan and CT-guided biopsy on histological analysis revealed a diagnosis of @entity1 of the presacral space. The @entity0 subsequently underwent an abdominoperineal excision of the rectum. Conclusions. This case highlights the importance of tailgut cysts as a differential diagnosis of presacral masses. It is a rare congenital lesion developing from remnants of the embryonic postanal gut and is predominantly benign in nature. Approximately half of cases remain asymptomatic; therefore, diagnosis is often delayed. Magnetic resonance imaging is the investigation of choice and an awareness of the possibility of malignant potential is critical to avoiding missed diagnosis and subsequent morbidity. Complete surgical excision allows accurate diagnosis, confirmation of oncological clearance, and prevention of mortality.

title: XXXX within a Tail Gut Cyst: A Case of @entity1 .

answer: @entity1


abstract: Purpose. Tailgut cysts with malignant transformation are rare entities. We discuss the diagnostic strategy and treatment of a @entity1 within a tailgut cyst. Methods. In this study we report on the case of a 61-year-old @entity0 with a @entity1 arising within a tailgut cyst and an overview of the literature emphasising the histopathological characteristics and differential diagnosis. Results. Our @entity0 presented with @entity3 , @entity2 , and increased urgency of defecation. MRI scan and CT-guided biopsy on histological analysis revealed a diagnosis of @entity1 of the presacral space. The @entity0 subsequently underwent an abdominoperineal excision of the rectum. Conclusions. This case highlights the importance of tailgut cysts as a differential diagnosis of presacral masses. It is a rare congenital lesion developing from remnants of the embryonic postanal gut and is predominantly benign in nature. Approximately half of cases remain asymptomatic; therefore, diagnosis is often delayed. Magnetic resonance imaging is the investigation of choice and an awareness of the possibility of malignant potential is critical to avoiding missed diagnosis and subsequent morbidity. Complete surgical excision allows accurate diagnosis, confirmation of oncological clearance, and prevention of mortality.

title: @entity1 within a Tail Gut Cyst: A Case of XXXX .

answer: @entity1


abstract: A randomized, double blind, placebo-controlled study (placebo and @entity2 1 or 5 mg/die) was carried out in 34 @entity0 with @entity4 ( @entity4 ). After 12 months of treatment all @entity0 received @entity2 5 mg/die. Follow-up ranges from 18 to 36 months. One year after treatment, @entity0 receiving @entity2 1 or 5 mg/die, showed significant decrease (one-way ANOVA) of serum @entity3 (-70.1% and -69.6%, respectively), serum @entity5 (-50% and -50.8%, respectively) and prostate volume (-36.3% and -31.8%, respectively). Comparable modifications of such parameters were observed in the placebo group only during the second year of the study when they were shifted to @entity2 treatment (5 mg/die). No increase of serum @entity1 was observed in any group. Maximum urinary flow rate increased on the average, after one year, by 2.6 and 3.6 ml/s in @entity0 receiving @entity2 1 and 5 mg/die, respectively; a 1.3 ml/s increase occurred in the placebo group. The total urinary symptom score (Boyarsky) decreased in all three @entity0 groups. Results of this study show that a few months are necessary to exert a significant therapeutic effect. The drug is well tolerated and does not decrease the @entity0 's sexual activity. @entity2 certainly opens new perspectives in the treatment of @entity4 .

title: [New prospective therapy for @entity4 with XXXX ].

answer: @entity2


abstract: A randomized, double blind, placebo-controlled study (placebo and @entity2 1 or 5 mg/die) was carried out in 34 @entity0 with @entity4 ( @entity4 ). After 12 months of treatment all @entity0 received @entity2 5 mg/die. Follow-up ranges from 18 to 36 months. One year after treatment, @entity0 receiving @entity2 1 or 5 mg/die, showed significant decrease (one-way ANOVA) of serum @entity3 (-70.1% and -69.6%, respectively), serum @entity5 (-50% and -50.8%, respectively) and prostate volume (-36.3% and -31.8%, respectively). Comparable modifications of such parameters were observed in the placebo group only during the second year of the study when they were shifted to @entity2 treatment (5 mg/die). No increase of serum @entity1 was observed in any group. Maximum urinary flow rate increased on the average, after one year, by 2.6 and 3.6 ml/s in @entity0 receiving @entity2 1 and 5 mg/die, respectively; a 1.3 ml/s increase occurred in the placebo group. The total urinary symptom score (Boyarsky) decreased in all three @entity0 groups. Results of this study show that a few months are necessary to exert a significant therapeutic effect. The drug is well tolerated and does not decrease the @entity0 's sexual activity. @entity2 certainly opens new perspectives in the treatment of @entity4 .

title: [New prospective therapy for XXXX with @entity2 ].

answer: @entity4


abstract: BACKGROUND: @entity2 is one common @entity0 requiring newer targets and newer drugs for its efficient management. In the recent days brain renin angiotensin system has gained immense importance because of its involvement in @entity3 regulation. OBJECTIVE: To evaluate and compare antiepileptic activity of different doses @entity6 and @entity7 on @entity9 and PTZ induced @entity3 models. MATERIALS AND METHODS: Swiss albino @entity1 weighing around 25-30g of either sex were divided into 6 groups: Control ( Distilled Water- 10ml/kg), Standard - @entity4 (40mg/kg), O1 - @entity6 (2.5mg/kg), O2 - @entity6 (5mg/kg), T1 - @entity7 (5mg/kg), T2 - @entity7 (10mg/kg). After 1hour of administration of control , test and standard drugs (orally), @entity3 were induced by administering PTZ (70mg/kg - i.p.) in PTZ model. @entity3 latency was the parameter recorded. In @entity9 model, suppression of tonic hind limb extension was taken as measure of efficacy. RESULT: The results were analysed by one-way-ANOVA followed by Bonferroni's multiple comparison test. In @entity9 test, dose dependently @entity6 and @entity7 significantly reduced the duration of @entity5 in comparison to control (p<0.05). T2 - 9 + 0.89secs significantly reduced the tonic hind limb extension compared to other test groups (p<0.05). The percentage inhibition of @entity3 was T2-44.3%, O2-28.2%, T1-17.5%, O1- 12.3% respectively. In PTZ test, dose dependently @entity6 and @entity7 produced significant increase in @entity3 latency (p<0.05). T2 - 206.6+9.83secs significantly increased @entity3 latency compared to other test groups (p<0.05). Percentage protection from @entity3 is T2-52.6%, O2- 45.13%, T1- 37.5%, O1- 38.4% respectively. CONCLUSION: @entity8 antagonist, @entity7 and @entity6 in a dose dependent manner showed increase in antiepileptic activity. Temisartan at higher dose produced significant antiepileptic activity in comparison to @entity6 .

title: Evaluation and comparison of anticonvulsant activity of XXXX and @entity6 in experimentally induced animal models of @entity2 .

answer: @entity7


abstract: BACKGROUND: @entity2 is one common @entity0 requiring newer targets and newer drugs for its efficient management. In the recent days brain renin angiotensin system has gained immense importance because of its involvement in @entity3 regulation. OBJECTIVE: To evaluate and compare antiepileptic activity of different doses @entity6 and @entity7 on @entity9 and PTZ induced @entity3 models. MATERIALS AND METHODS: Swiss albino @entity1 weighing around 25-30g of either sex were divided into 6 groups: Control ( Distilled Water- 10ml/kg), Standard - @entity4 (40mg/kg), O1 - @entity6 (2.5mg/kg), O2 - @entity6 (5mg/kg), T1 - @entity7 (5mg/kg), T2 - @entity7 (10mg/kg). After 1hour of administration of control , test and standard drugs (orally), @entity3 were induced by administering PTZ (70mg/kg - i.p.) in PTZ model. @entity3 latency was the parameter recorded. In @entity9 model, suppression of tonic hind limb extension was taken as measure of efficacy. RESULT: The results were analysed by one-way-ANOVA followed by Bonferroni's multiple comparison test. In @entity9 test, dose dependently @entity6 and @entity7 significantly reduced the duration of @entity5 in comparison to control (p<0.05). T2 - 9 + 0.89secs significantly reduced the tonic hind limb extension compared to other test groups (p<0.05). The percentage inhibition of @entity3 was T2-44.3%, O2-28.2%, T1-17.5%, O1- 12.3% respectively. In PTZ test, dose dependently @entity6 and @entity7 produced significant increase in @entity3 latency (p<0.05). T2 - 206.6+9.83secs significantly increased @entity3 latency compared to other test groups (p<0.05). Percentage protection from @entity3 is T2-52.6%, O2- 45.13%, T1- 37.5%, O1- 38.4% respectively. CONCLUSION: @entity8 antagonist, @entity7 and @entity6 in a dose dependent manner showed increase in antiepileptic activity. Temisartan at higher dose produced significant antiepileptic activity in comparison to @entity6 .

title: Evaluation and comparison of anticonvulsant activity of @entity7 and XXXX in experimentally induced animal models of @entity2 .

answer: @entity6


abstract: BACKGROUND: @entity2 is one common @entity0 requiring newer targets and newer drugs for its efficient management. In the recent days brain renin angiotensin system has gained immense importance because of its involvement in @entity3 regulation. OBJECTIVE: To evaluate and compare antiepileptic activity of different doses @entity6 and @entity7 on @entity9 and PTZ induced @entity3 models. MATERIALS AND METHODS: Swiss albino @entity1 weighing around 25-30g of either sex were divided into 6 groups: Control ( Distilled Water- 10ml/kg), Standard - @entity4 (40mg/kg), O1 - @entity6 (2.5mg/kg), O2 - @entity6 (5mg/kg), T1 - @entity7 (5mg/kg), T2 - @entity7 (10mg/kg). After 1hour of administration of control , test and standard drugs (orally), @entity3 were induced by administering PTZ (70mg/kg - i.p.) in PTZ model. @entity3 latency was the parameter recorded. In @entity9 model, suppression of tonic hind limb extension was taken as measure of efficacy. RESULT: The results were analysed by one-way-ANOVA followed by Bonferroni's multiple comparison test. In @entity9 test, dose dependently @entity6 and @entity7 significantly reduced the duration of @entity5 in comparison to control (p<0.05). T2 - 9 + 0.89secs significantly reduced the tonic hind limb extension compared to other test groups (p<0.05). The percentage inhibition of @entity3 was T2-44.3%, O2-28.2%, T1-17.5%, O1- 12.3% respectively. In PTZ test, dose dependently @entity6 and @entity7 produced significant increase in @entity3 latency (p<0.05). T2 - 206.6+9.83secs significantly increased @entity3 latency compared to other test groups (p<0.05). Percentage protection from @entity3 is T2-52.6%, O2- 45.13%, T1- 37.5%, O1- 38.4% respectively. CONCLUSION: @entity8 antagonist, @entity7 and @entity6 in a dose dependent manner showed increase in antiepileptic activity. Temisartan at higher dose produced significant antiepileptic activity in comparison to @entity6 .

title: Evaluation and comparison of anticonvulsant activity of @entity7 and @entity6 in experimentally induced animal models of XXXX .

answer: @entity2


abstract: BACKGROUND: Morbidity related to @entity3 and @entity1 which are well known sequel after burns remains high and in fact has increased as more severely burned @entity0 are surviving. This study was undertaken in order to assess the varied clinical presentation, precipitating factors, preventive measures, treatment modalities of neck @entity1 and evaluate the results after surgical procedures. MATERIALS AND METHODS: This hospital based study was conducted on @entity0 admitted in our institution with proven cases of Post @entity1 from 1st August 2009 to 31st July 2011. Twenty two @entity0 of post @entity1 who underwent operative treatment were included. OBSERVATION: 10 of 22 cases were in the middle age group i.e. between 21-30 years. There were 5 males and 17 females. @entity4 was the commonest aetiology. Fourteen @entity0 were treated within 1 year of burns for functional disability. Excisional release was performed in 13 and incisional release in 9 of our @entity0 . Resurfacing with STSG (split thickness skin graft) was carried out in 19 cases and a local or regional flap with or without a graft in 3 @entity0 . @entity2 and recontracture were the commonest late complications and occurred in 3 cases. Good to fair results were obtained in 19 @entity0 CONCLUSION: Local flaps have many advantages and are to be used whenever possible. It is preferable to place the grafts if used in the area surrounding the neck (donor site of flap) or at least in the non-visible area of the neck (submental area). When a combination of flap _ graft is used, it's preferable to place the flap in a horizontal intersecting fashion in between the two patches of the graft. A follow up program for reasonable period is highly desired.

title: Post burn XXXX neck: clinical profile and management.

answer: @entity1


abstract: The treatment of locally advanced @entity3 is controversial, as there are several possible treatment options. The aims of temporary @entity4 deprivation prior to radical prostatectomy are to achieve downgrading and downstaging of the @entity1 , an increase in local control, a decrease in morbidity and operative sequelae, a decrease in the time to progression, and an improvement in survival. A retrospective study has been carried out on 100 @entity0 who underwent radical prostatectomy between 1988 and 1992. Forty @entity0 received @entity4 deprivation therapy followed by prostatectomy, while the remaining 60 acted as controls, undergoing prostatectomy alone. Treated @entity0 had a 40-50% reduction in prostate volume after 3 months, facilitating dissection of the prostate, reducing intraoperative @entity2 , and reducing operation time. Of these 40 treated @entity0 , one third showed clinical downstaging; one @entity0 staged initially as T2/B was downstaged to PT0. The proportion of @entity0 with positive surgical margins was 32% in the group treated preoperatively, compared with 57% in untreated @entity0 . Treated @entity0 also recovered full continence more rapidly after the operation than @entity0 who underwent prostatectomy alone. After @entity4 blockade, serum @entity5 levels returned to normal (< 4 ng/ml) in 37 of the 40 @entity0 . Of these @entity0 , 22 had undetectable serum @entity5 levels (< 0.25 ng/ml), showing a definite reduction in @entity1 activity. @entity5 levels after 3 months of neoadjuvant hormonal treatment might play a useful predictive role in selecting @entity0 before radical prostatectomy, since 86% with undetectable @entity5 had @entity1 confined to the gland (T2/B2), while @entity0 who still had @entity5 > 4 ng/ml all had stage T3-T4 @entity1 . Although downstaging was confirmed pathologically in only 13% of @entity0 , this is of significance when the total number of @entity0 with locally advanced @entity3 is considered and, therefore, may have implications for survival in the future. Prospective randomized studies should provide conclusive information on the potential benefit of this approach.

title: Neoadjuvant XXXX blockade prior to prostatectomy: a retrospective study and critical review.

answer: @entity4


abstract: Although recurrent @entity6 have been identified in several histologic subtypes of @entity1 , no consistent rearrangement has yet been found in @entity2 . Cytogenetic analyses of nine cases of @entity2 are reported, including seven newly diagnosed @entity0 and two recurrent @entity0 . There were seven high-grade @entity2 , one @entity5 , and one well-differentiated @entity1 . All @entity0 were studied in short-term primary culture. Modal number ranged from near diploid to near triploid. Seven @entity0 had complex karyotypes with multiple structural abnormalities; two had only normal karyotypes. The @entity4 gene on chromosome 13 and the @entity3 gene on chromosome 17 have been involved in @entity2 . @entity0 had loss of a whole copy of chromosome 13, and three of these also had a loss of a whole copy of chromosome 17. However, these losses were observed in the setting of numerous other chromosome losses. @entity7 were observed, many involving additions of unidentified material, unbalanced translocations, or deletions. @entity7 with similar breakpoints involving 6q, 8q, 9q, and 14p were seen in two or three @entity0 each. When the @entity0 in this series were added to the 18 published cases, the pericentromeric regions of chromosomes 1, 3, and 14, and segments 6q15-21, 8q24, 9q34, 12p13, 17p13, and 19q13, were found to be involved in five or more structural rearrangements. Molecular analyses of these chromosome regions may yield genes important in the pathogenesis of @entity2 .

title: Chromosome analysis of nine XXXX .

answer: @entity2


abstract: Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) have been implicated in the development and progression of many @entity1 , but data for primary @entity9 (PNC) of the skin are lacking. The aim of the study was to assess the expression of MMPs and TIMPs in PNC and to evaluate their prognostic significance. Expression of @entity10 , @entity2 , @entity4 , @entity3 , @entity12 , @entity5 , and @entity6 and @entity8 , @entity7 , and @entity11 was evaluated by immunohistochemistry on 23 samples of PNC of the skin. The results were matched with clinical features and @entity0 survival. In the 23 specimens of PNC, high (>20% of positive neoplastic cells) @entity10 expression was found in 13 (56.5%) cases. @entity2 was evidenced in 12 (52.1%) cases, 8 (34.7%) of which showed high expression in neoplastic cells. @entity4 was detected in 11 cases (47.8%), with high expression in 9 (39.1%) of them. High @entity3 expression was observed in 3 (13%) cases, whereas high @entity6 expression was detected in 11 (47.8%) specimens. Expression of @entity8 by neoplastic cells was found in 8 (34.7%) cases, with high expression in 3 cases, whereas high @entity11 expression was detected in 21 (91.3%) cases. No immunoreactivity for @entity12 , @entity5 , or @entity7 was found. Statistical analysis failed to identify a significant correlation between MMP/ @entity8 expression and clinical parameters. By univariate analysis, stage >I (P = 0.01), high expression of @entity10 (P = 0.04) and @entity4 (P = 0.01) resulted significant negative prognostic factors, whereas by multivariate analysis, stage was the only factor that affected survival (P = 0.02). Our results suggest that @entity10 and @entity4 may influence the invasive and metastatic potential of PNCs. It is conceivable that future attempts to specifically block @entity10 and @entity4 activity may provide a novel means to inhibit invasiveness and distant spread in selected @entity0 with PNC.

title: Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary XXXX of the skin.

answer: @entity9


abstract: The interaction of several basic peptides with @entity0 mitochondria has been analyzed. The peptides were selected for their ability to block a cationic channel of the outer membrane, the peptide-sensitive channel. These peptides possess common characteristics, such as a net positive charge superior to 2 and the capacity to form amphiphilic structures. They can be divided into two classes as follows: peptides of class I derived from mitochondrial signal peptides, such as the presequence of @entity1 , e.g. pCyt OX IV (1-12) Y; and peptides of class II unrelated to the mitochondria, such as @entity2 (1-13). Class I peptides inhibited the translocation of a chimeric protein, cytochrome b2-DHFR, into the mitochondrial matrix, whereas peptides of class II failed to inhibit this import. Experiments with iodinated pCyt OX IV (1-12) Y and @entity2 (1-13) showed, however, that both types of peptides were imported into @entity0 mitochondria in vitro and subsequently degraded. At 30 degrees C, two import mechanisms could be distinguished; the mitochondrial presequences (class I) were translocated into the matrix in a temperature- and potential-sensitive manner, probably along the general import pathway, while class II @entity2 (1-13) was imported into the intermembrane space by a process that was neither temperature- nor potential-sensitive. At 0 degree C, both peptides were imported in a class II manner. The class II characteristics suggested the existence of a direct pathway into the intermembrane space, which may be associated with the peptide-sensitive channel. This hypothesis is substantiated by the competition for the import into the mitochondria between peptides of the two classes. The import of pCyt OX (1-12) Y was inhibited at 30 degrees C only by peptides of class I, IV whereas, at 0 degree C, this import was also inhibited by peptides of class II. Import of peptides of the latter class was inhibited by peptides of the two classes both at 0 degree C and 30 degrees C.

title: Basic peptides can be imported into XXXX mitochondria by two distinct targeting pathways. Involvement of the peptide-sensitive channel of the outer membrane.

answer: @entity0


abstract: OBJECTIVE: The maternal autonomic nervous system (ANS) has received little attention in the investigation of biological mechanisms linking prenatal stress to fetal @entity1 (F) excess. In vitro, @entity3 and @entity4 inhibit placental 11b-hydroxysteroid dehydrogenase type 2 (11b- @entity6 ), which protects the fetus from F overexposure by inactivating it to @entity2 (E). Here, we investigated the acute ANS stress response to an amniocentesis and its association with amniotic fluid F, E, and E/(E + F) as a marker of fetoplacental 11b- @entity6 activity. METHODS: An aliquot of amniotic fluid was obtained from 34 healthy, second-trimester pregnant @entity0 undergoing amniocentesis. Repeated assessment of mood states served to examine the psychological stress response to amniocentesis. Saliva samples were collected to measure stress-induced changes in salivary a-amylase concentrations in response to amniocentesis. Cardiac parameters were measured continuously. RESULTS: Undergoing amniocentesis induced significant @entity5 . Low-frequency (LF)/high-frequency (HF) baseline, suggested to reflect sympathovagal balance, was negatively correlated with amniotic E/(E + F) (r=-0.53, p = .002) and positively with F (r = 0.62, p < .001). In contrast, a stronger acute LF/HF response was positively associated with E/(E + F) (r = 0.44, p = .012) and negatively with F (r=-0.40, p = .025). CONCLUSIONS: These findings suggest that the maternal ANS is involved in the regulation of the fetoplacental barrier to stress. Allostatic processes may have been initiated to counterbalance acute stress effects. In contrast, higher LF/HF baseline values, possibly indicative of chronic stress exposure, may have inhibited 11b- @entity6 activity in the fetoplacental unit. These results parallel animal findings of up-regulated placental 11b- @entity6 in response to acute stress but impairment under chronic stress.

title: The Acute Autonomic Stress Response and Amniotic Fluid Glucocorticoids in Second-Trimester Pregnant XXXX .

answer: @entity0


abstract: The pharmacological treatment of @entity1 overlaps with the treatment of @entity3 . The primary objective of this treatment is to slow the progression of disease and improve quality and length of life. All @entity0 , including those with asymptomatic dysfunction of the left ventricle, ought to receive angiotensin converting enzyme inhibitors, (in the case of intolerance, angiotensin receptor blockers), and beta blockers. The results of studies involving aliskiren have been, so far, disappointing. In symptomatic @entity3 NYHA II-IV diuretics and mineralcorticoid receptor antagonists should be added to treatment. @entity9 is recommended in the event of @entity5 , and otherwise only in the event of NYHA III and IV. @entity10 is recommended for @entity0 with sinus rhythm and pulse rate of > 70/min. In decompensation of @entity3 , @entity2 , phosphodiesterase inhibitors or @entity8 are administered over the short-term. Of the recent treatment options, the @entity6 blocker and @entity4 A1 receptor antagonist ( @entity11 ) were disappointing. One treatment with potential for the future is omecamtiv mecarbil, a heart @entity7 activator.

title: Pharmacotherapy of XXXX .

answer: @entity1


abstract: INTRODUCTION: @entity3 is the most common @entity4 with a variable clinical manifestation depending on the number of allele mutations (asymptomatic/mild @entity2 if 1-2 allele mutations, severe disease if 3-4 allele mutations). A study was conducted from May 2011 on @entity4 found in the neonatal screening in the autonomous community of the Basque Country (CAPV). OBJECTIVES: To analyze the impact of @entity3 in this area and the effectiveness of its neonatal screening. METHODS: A review was made of @entity0 with a positive gene study for @entity3 over a 2-year period (2012-2013) and an analysis was made of the age at diagnosis, ethnic group, analytical result, and treatment. RESULTS: The genetic study was performed on 107 @entity0 , of which 61 had some mutation, with 62% having one allele mutations and 38% with two alleles. The mean age at diagnosis was 31 years, with 28% being younger than eighteen years old. Most of the @entity0 were European with a significant number of Africans (26%) and Arabs (13%). All @entity0 were asymptomatic, and 28% had mild @entity2 . Two @entity0 were diagnosed by neonatal screening. Most of them did not need any treatment or only required @entity1 therapy. CONCLUSIONS: The detection of one or two alpha gene mutations has no clinical impact, but allows genetic counseling. No @entity0 was found with 3-4 mutations or severe symptoms in our region. Contrarily to the diagnosis of other diseases, our results does not support that routine neonatal screening for @entity3 has any clinical impact in our community.

title: [Clinical consequences of XXXX in the basque country, Spain. Impact of neonatal screening.]

answer: @entity3


abstract: OBJECTIVES: In this study, we aim to analyze the different spreading patterns, prognostic factors and treatment outcomes of @entity7 ( @entity7 ) and @entity3 (NPCs). DESIGN, SETTING AND @entity0 : The current study report on a retrospective analysis of oncologic outcome of 76 pathologically confirmed consecutive cases of @entity4 ( @entity4 ), including 31 @entity7 , 33 @entity5 ( @entity5 ) and 12 @entity6 ( @entity6 ). MAIN OUTCOME MEASURE: Overall survival rates (OS) and disease-free survival rates (DFS). RESULTS: In 12 @entity0 with @entity2 , there were @entity5 (n=9), @entity7 (n=2) and @entity6 (n=1) (p=0.016). CT/MRI detected CN involvements were found in 22 @entity0 . Lymph node @entity1 were observed in 25.8% of @entity7 (n=8), 12.1% of @entity5 (n=4) and 8.3% of @entity6 (n=1). Significant differences were observed in 5-year overall survival rates (OS) and disease-free survival rates (DFS) between @entity0 with and without CT/MRI-detected CN involvement (p=0.002 and p=0.002, respectively), and similar results were found between @entity0 with and without lymph node @entity1 (p=0.002 and p=0.018, respectively). In 37 @entity0 with early stage disease (stage I-II), significant differences were observed in 5-year OS and DFS rates between the surgical and non-surgical treated groups (p=0.031 and p=0.012, respectively). In 39 @entity0 with advanced stage disease (stage III-IV), significant or marginally differences were observed in DFS and OS between the chemoradiotherapy group and non-chemoradiotherapy group (p=0.007 and p=0.062, respectively). CONCLUSIONS: @entity5 has a higher CN invasion than @entity7 and @entity6 , and @entity7 has the highest rate of lymphatic metastases. CT/MRI detected CN involvements and lymph node @entity1 indicate a negative impact on the prognosis. The outcome of surgical @entity0 in our series is encouraging in early stage @entity7 and NPCs, and chemoradiotherapy may be the optimal treatment for the advanced stage @entity0 . This article is protected by copyright. All rights reserved.

title: Spreading Patterns, Prognostic factors and Treatment Outcomes of XXXX and @entity3 .

answer: @entity7


abstract: OBJECTIVES: In this study, we aim to analyze the different spreading patterns, prognostic factors and treatment outcomes of @entity7 ( @entity7 ) and @entity3 (NPCs). DESIGN, SETTING AND @entity0 : The current study report on a retrospective analysis of oncologic outcome of 76 pathologically confirmed consecutive cases of @entity4 ( @entity4 ), including 31 @entity7 , 33 @entity5 ( @entity5 ) and 12 @entity6 ( @entity6 ). MAIN OUTCOME MEASURE: Overall survival rates (OS) and disease-free survival rates (DFS). RESULTS: In 12 @entity0 with @entity2 , there were @entity5 (n=9), @entity7 (n=2) and @entity6 (n=1) (p=0.016). CT/MRI detected CN involvements were found in 22 @entity0 . Lymph node @entity1 were observed in 25.8% of @entity7 (n=8), 12.1% of @entity5 (n=4) and 8.3% of @entity6 (n=1). Significant differences were observed in 5-year overall survival rates (OS) and disease-free survival rates (DFS) between @entity0 with and without CT/MRI-detected CN involvement (p=0.002 and p=0.002, respectively), and similar results were found between @entity0 with and without lymph node @entity1 (p=0.002 and p=0.018, respectively). In 37 @entity0 with early stage disease (stage I-II), significant differences were observed in 5-year OS and DFS rates between the surgical and non-surgical treated groups (p=0.031 and p=0.012, respectively). In 39 @entity0 with advanced stage disease (stage III-IV), significant or marginally differences were observed in DFS and OS between the chemoradiotherapy group and non-chemoradiotherapy group (p=0.007 and p=0.062, respectively). CONCLUSIONS: @entity5 has a higher CN invasion than @entity7 and @entity6 , and @entity7 has the highest rate of lymphatic metastases. CT/MRI detected CN involvements and lymph node @entity1 indicate a negative impact on the prognosis. The outcome of surgical @entity0 in our series is encouraging in early stage @entity7 and NPCs, and chemoradiotherapy may be the optimal treatment for the advanced stage @entity0 . This article is protected by copyright. All rights reserved.

title: Spreading Patterns, Prognostic factors and Treatment Outcomes of @entity7 and XXXX .

answer: @entity3


abstract: BACKGROUND: Whole @entity2 is a putative outcome measure in monitoring relapsing-remitting @entity1 (RRMS). With the ongoing MRI transformation from 1.5T to 3T, there is an unmet need to calibrate this change. We evaluated brain parenchymal volumes (BPVs) from 1.5T versus 3T in @entity1 and normal controls (NC). METHODS: We studied @entity1 [n = 26, age (mean, range) 43 (21-55), 22 (85%) RRMS, Expanded Disability Status Scale (EDSS) 1.98 (0-6.5), timed 25 foot walk (T25FW) 5.95 (3.2-33.0 seconds)] and NC [n = 9, age 45 (31-53)]. Subjects underwent 1.5T (Phillips) and 3T (GE) 3-dimensional T1-weighted scans to derive normalized @entity4 from an automated SIENAX pipeline. Neuropsychological testing was according to consensus panel recommendations. RESULTS: @entity3 .5T was higher than @entity3 T [mean (95% CI) + 45.7 mL (+35.3, +56.1), P < .00001], most likely due to improved tissue-CSF contrast at 3T. @entity3 T showed a larger volume decrease and larger effect size in detecting @entity2 in @entity1 versus NC [-74.5 mL (-126.5, -22.5), P = .006, d = .92] when compared to @entity3 .5T [-51.3.1 mL (-99.8, -2.8), P = .04, d = .67]. Correlations between @entity3 .5T and EDSS (r = -.43, P = .027) and @entity3 T and EDSS (r = -.49, P = .011) and between @entity3 .5T and T25FW (r = -.46, P = .018) and @entity3 T and T25FW (r = -.56, P = .003) slightly favored 3T. @entity4 -cognition correlations were significant (P < .05) for 6 of 11 subscales to a similar degree at 1.5T (r range = .44-.58) and 3T (r range = .43-.53). CONCLUSIONS: Field strength may impact whole brain volume measurements in @entity0 with @entity1 though the differences are not too divergent between 1.5T and 3T.

title: Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and @entity0 with XXXX .

answer: @entity1


abstract: BACKGROUND: Whole @entity2 is a putative outcome measure in monitoring relapsing-remitting @entity1 (RRMS). With the ongoing MRI transformation from 1.5T to 3T, there is an unmet need to calibrate this change. We evaluated brain parenchymal volumes (BPVs) from 1.5T versus 3T in @entity1 and normal controls (NC). METHODS: We studied @entity1 [n = 26, age (mean, range) 43 (21-55), 22 (85%) RRMS, Expanded Disability Status Scale (EDSS) 1.98 (0-6.5), timed 25 foot walk (T25FW) 5.95 (3.2-33.0 seconds)] and NC [n = 9, age 45 (31-53)]. Subjects underwent 1.5T (Phillips) and 3T (GE) 3-dimensional T1-weighted scans to derive normalized @entity4 from an automated SIENAX pipeline. Neuropsychological testing was according to consensus panel recommendations. RESULTS: @entity3 .5T was higher than @entity3 T [mean (95% CI) + 45.7 mL (+35.3, +56.1), P < .00001], most likely due to improved tissue-CSF contrast at 3T. @entity3 T showed a larger volume decrease and larger effect size in detecting @entity2 in @entity1 versus NC [-74.5 mL (-126.5, -22.5), P = .006, d = .92] when compared to @entity3 .5T [-51.3.1 mL (-99.8, -2.8), P = .04, d = .67]. Correlations between @entity3 .5T and EDSS (r = -.43, P = .027) and @entity3 T and EDSS (r = -.49, P = .011) and between @entity3 .5T and T25FW (r = -.46, P = .018) and @entity3 T and T25FW (r = -.56, P = .003) slightly favored 3T. @entity4 -cognition correlations were significant (P < .05) for 6 of 11 subscales to a similar degree at 1.5T (r range = .44-.58) and 3T (r range = .43-.53). CONCLUSIONS: Field strength may impact whole brain volume measurements in @entity0 with @entity1 though the differences are not too divergent between 1.5T and 3T.

title: Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and XXXX with @entity1 .

answer: @entity0


abstract: OBJECTIVE: This study was designed to investigate the potentially prognostic indicators of early @entity2 ( @entity2 ), including @entity4 ) status. METHODS: A total of 336 @entity0 with T2N0-1M0 LSCC were included in this study. Clinical data were collected from archival documents, and @entity5 and @entity3 ( @entity3 ) expression were detected. RESULTS: A total of 32/318 cases of high-risk @entity5 and 10/336 cases of @entity3 ( @entity3 ) overexpression were found. Three hundred eighteen @entity1 were classified into a three-class model according to @entity5 and @entity3 ( @entity3 ) expression: class I, HPV+/ @entity3 +; class II, HPV+/ @entity3 -; and class III, HPV-/ @entity3 -. Class III had a trend of decreased @entity6 ( @entity6 ) (P  =  0.076) and a markedly low @entity7 ( @entity7 ) (P  =  0.022) compared with class I and class II. HPV-positive cases (class I plus class II) had a significantly longer @entity6 (P  =  0.038) and @entity7 (P  =  0.006). In multivariate analysis, HPV-positive (P  =  0.020), nonanemia (P = 0.011), and N0 stage (P  =  0.005) were significant predictors for high @entity7 . But only HPV-positive (P  =  0.047) and nonanemia (P  <  0.001) were significant predictors for superior @entity6 . CONCLUSION: A trend of discrete survival among HPV+/ @entity3 +, HPV+/ @entity3 -, and HPV-/ @entity3 classes was found in early @entity2 . We suggest that @entity5 and hemoglobin level are the potential factors that can stratify outcome of early @entity2 .

title: @entity5 and Anemia Status Stratify the Survival of Early T2 XXXX .

answer: @entity2


abstract: OBJECTIVE: This study was designed to investigate the potentially prognostic indicators of early @entity2 ( @entity2 ), including @entity4 ) status. METHODS: A total of 336 @entity0 with T2N0-1M0 LSCC were included in this study. Clinical data were collected from archival documents, and @entity5 and @entity3 ( @entity3 ) expression were detected. RESULTS: A total of 32/318 cases of high-risk @entity5 and 10/336 cases of @entity3 ( @entity3 ) overexpression were found. Three hundred eighteen @entity1 were classified into a three-class model according to @entity5 and @entity3 ( @entity3 ) expression: class I, HPV+/ @entity3 +; class II, HPV+/ @entity3 -; and class III, HPV-/ @entity3 -. Class III had a trend of decreased @entity6 ( @entity6 ) (P  =  0.076) and a markedly low @entity7 ( @entity7 ) (P  =  0.022) compared with class I and class II. HPV-positive cases (class I plus class II) had a significantly longer @entity6 (P  =  0.038) and @entity7 (P  =  0.006). In multivariate analysis, HPV-positive (P  =  0.020), nonanemia (P = 0.011), and N0 stage (P  =  0.005) were significant predictors for high @entity7 . But only HPV-positive (P  =  0.047) and nonanemia (P  <  0.001) were significant predictors for superior @entity6 . CONCLUSION: A trend of discrete survival among HPV+/ @entity3 +, HPV+/ @entity3 -, and HPV-/ @entity3 classes was found in early @entity2 . We suggest that @entity5 and hemoglobin level are the potential factors that can stratify outcome of early @entity2 .

title: XXXX and Anemia Status Stratify the Survival of Early T2 @entity2 .

answer: @entity5


abstract: The IGF binding proteins (IGFBPs) comprise at least six distinct species which may modulate the action of IGFs. IGFs are important regulators of fetal growth and differentiation. We have studied the mRNA expression of the six IGFBPs during post-implantation embryogenesis (day 11-18) by in situ hybridization techniques. Expression of @entity7 was detected in @entity1 conceptuses after day 12 of gestation and seemed restricted to the liver. Transcripts for @entity5 were detected in various tissues and were found in all stages tested. In contrast, expression of @entity9 could be detected only weakly in late gestational embryos. Comparison of the expression pattern of @entity5 , which were found widely distributed in @entity1 conceptuses, revealed that @entity2 was expressed mainly in the ectodermal layer and also in the mesoderm derived part of the tongue (day 13.5). Transcripts for @entity3 however, only were detected in the mesoderm derived tissues, whereas expression of @entity4 was restricted to the ectodermal layer. A similar distribution pattern was observed in the lung. In general, expression of @entity8 was detected in the same cells, whereas @entity6 were expressed mainly in different cell types. In rodents as in the @entity0 there is widespread expression of the genes coding IGFs, the IGFBPs and the receptors during pre- and postimplantation embryogenesis. These data support the assumption that the IGFs play an important role during embryogenesis.

title: Gene expression of the IGF binding proteins during post-implantation embryogenesis of the XXXX ; comparison with the expression of IGF-I and -II and their receptors in rodent and @entity0 .

answer: @entity1


abstract: The IGF binding proteins (IGFBPs) comprise at least six distinct species which may modulate the action of IGFs. IGFs are important regulators of fetal growth and differentiation. We have studied the mRNA expression of the six IGFBPs during post-implantation embryogenesis (day 11-18) by in situ hybridization techniques. Expression of @entity7 was detected in @entity1 conceptuses after day 12 of gestation and seemed restricted to the liver. Transcripts for @entity5 were detected in various tissues and were found in all stages tested. In contrast, expression of @entity9 could be detected only weakly in late gestational embryos. Comparison of the expression pattern of @entity5 , which were found widely distributed in @entity1 conceptuses, revealed that @entity2 was expressed mainly in the ectodermal layer and also in the mesoderm derived part of the tongue (day 13.5). Transcripts for @entity3 however, only were detected in the mesoderm derived tissues, whereas expression of @entity4 was restricted to the ectodermal layer. A similar distribution pattern was observed in the lung. In general, expression of @entity8 was detected in the same cells, whereas @entity6 were expressed mainly in different cell types. In rodents as in the @entity0 there is widespread expression of the genes coding IGFs, the IGFBPs and the receptors during pre- and postimplantation embryogenesis. These data support the assumption that the IGFs play an important role during embryogenesis.

title: Gene expression of the IGF binding proteins during post-implantation embryogenesis of the @entity1 ; comparison with the expression of IGF-I and -II and their receptors in rodent and XXXX .

answer: @entity0


abstract: BACKGROUND: To evaluate the effect of @entity1 prices and the implementation of smoke-free legislation on smoking cessation in Spain, by educational level, across the period 1993-2012. METHODS: National Health Surveys data for the above two decades were used to calculate smoking cessation in @entity0 aged 25-64 years. The relationship between @entity1 prices and smoking quit-ratio was estimated using multiple linear regression adjusted for time and the presence of smoke-free legislation. The immediate as well as the longer-term impact of the 2006 smoke-free law on quit-ratio was estimated using segmented linear regression analysis. The analyses were performed separately in @entity0 and @entity0 with high and low education, respectively. RESULTS: No relationship was observed between @entity1 prices and smoking quit-ratio, except in @entity0 having a low educational level, among whom a rise in price was associated with a decrease in quit-ratio. The smoke-free law altered the smoking quit-ratio in the short term and altered also pre-existing trends. Smoking quit-ratio increased immediately after the ban - though this increase was significant only among @entity0 with a low educational level - and then decreased in subsequent years except among @entity0 with a high educational level. CONCLUSION: A clear relationship between @entity1 prices and smoking quit-ratio was not observed in a recent period. After the implementation of smoke-free legislation the trend in the quit ratio in most of the socio-economic groups was different from the trend observed before implementation, so existing inequalities in smoking quit-ratio were not widened or narrowed.

title: Impact of XXXX prices and smoke-free policy on smoking cessation, by gender and educational group: Spain, 1993-2012.

answer: @entity1


abstract: We recently reported an unusual abundance of @entity0 (4-6 mM) in porcine allantoic fluid during early gestation. However, it is not known whether such high concentrations of @entity0 are unique for porcine allantoic fluid or whether they represent an important physiological phenomenon for mammals. The present study was conducted to test the hypothesis that @entity0 is also the most abundant @entity2 in ovine allantoic fluid. Allantoic and amniotic fluids, as well as fetal and maternal plasma samples, were obtained from ewes between Days 30 and 140 of gestation. @entity7 was the most abundant @entity2 in maternal uterine arterial plasma, representing approximately 25% of total @entity2 . @entity1 , @entity4 , @entity7 , plus @entity3 contributed approximately 50% of total @entity2 in fetal plasma. Fetal:maternal plasma ratios for @entity5 varied greatly, being less than 1 for @entity6 during late gestation, 1.5-3 for most @entity5 throughout gestation, and greater than 10 for @entity3 during late gestation. Marked changes were observed in @entity2 concentrations in amniotic and allantoic fluids associated with conceptus development. Concentrations of @entity1 , @entity8 , and @entity4 in allantoic fluid increased by 20-, 34-, and 18-fold, respectively, between Days 30 and 60 of gestation and were 24.7, 9.7, and 23.5 mM, respectively, on Day 60 of gestation (compared with 0.8 mM @entity0 ). Remarkably, @entity1 , @entity8 , plus @entity4 accounted for approximately 80% of total @entity2 in allantoic fluid during early gestation. @entity3 (16.5 mM) contributed approximately 60% of total @entity2 in allantoic fluid on Day 140 of gestation. These novel findings of the unusual abundance of traditionally classified nonessential @entity5 in allantoic fluid raise important questions regarding their roles in ovine conceptus development.

title: Developmental changes of XXXX in ovine fetal fluids.

answer: @entity5


abstract: @entity3 (MAP) from intravaginal sponges prolongs the lifespan of large ovarian follicles when administered after @entity2 (PGF2alpha)-induced luteolysis early in the luteal phase of ewes. The present study was designed to determine whether a PGF2alpha/MAP treatment applied at midcycle would alter the pattern of antral follicle growth and increase ovulation rate in nonprolific ewes. A single injection of PGF2alpha (15 mg, i.m.) was given, and an intravaginal MAP (60 mg) sponge was inserted for 6 days, on approximately Day 8 after ovulation, in 7 (experiment 1), 8 (experiment 2) or 11 (experiment 3) ultrasonographically monitored, cycling Western white-faced ewes; seven ewes (experiment 1) served as untreated controls. Blood samples were collected each day and also every 12 min for 6 h, halfway through the period of treatment with MAP (experiment 1), or every 4 h, from 1 day before to 1 day after sponging (experiment 2). Seventeen of 26 treated ewes (experiment 1, n = 6; experiment 2, n = 5; experiment 3, n = 6) ovulated 1 to 6 days after PGF2alpha, but this did not affect the emergence of ensuing follicular waves (experiments 1 and 2). These ovulations, confirmed by laparotomy and histological examinations of the ovaries (experiment 3), were not preceded by an increase in LH/FSH secretion and did not result in corpora lutea, as evidenced by transrectal ultrasonography and RIA of serum @entity1 (experiments 1 and 2). Following the removal of MAP sponges, the mean ovulation rate was 3.1 +/- 0.4 in treated ewes and 2.0 +/- 0.3 in control ewes (experiment 1; P < 0.05). In experiments 1 and 2, the ovulation rate after treatment (3.1 +/- 0.4 and 2.8 +/- 0.4) was also greater than the pretreatment rate (1.9 +/- 0.3 and 1.9 +/- 0.1, respectively). Ovulations of follicles from two consecutive waves before ovulation were seen in five treated but only in two control ewes (experiment 1), and in seven ewes in experiment 2. There were no significant differences between the MAP-treated and control ewes in mean daily serum concentrations of FSH and @entity0 , and no differences in the parameters of LH/FSH secretion, based on frequent blood sampling. Treatment of nonprolific Western white-faced ewes with PGF2alpha and MAP at midcycle changed follicular dynamics and increased ovulation rate by approximately 50%. These effects of MAP, in the absence of luteal @entity1 , may not be mediated by changes in gonadotropin secretion.

title: Effects of a 6-day treatment with @entity3 after XXXX alpha-induced luteolysis at midcycle on antral follicular development and ovulation rate in nonprolific Western white-faced ewes.

answer: @entity2


abstract: @entity3 (MAP) from intravaginal sponges prolongs the lifespan of large ovarian follicles when administered after @entity2 (PGF2alpha)-induced luteolysis early in the luteal phase of ewes. The present study was designed to determine whether a PGF2alpha/MAP treatment applied at midcycle would alter the pattern of antral follicle growth and increase ovulation rate in nonprolific ewes. A single injection of PGF2alpha (15 mg, i.m.) was given, and an intravaginal MAP (60 mg) sponge was inserted for 6 days, on approximately Day 8 after ovulation, in 7 (experiment 1), 8 (experiment 2) or 11 (experiment 3) ultrasonographically monitored, cycling Western white-faced ewes; seven ewes (experiment 1) served as untreated controls. Blood samples were collected each day and also every 12 min for 6 h, halfway through the period of treatment with MAP (experiment 1), or every 4 h, from 1 day before to 1 day after sponging (experiment 2). Seventeen of 26 treated ewes (experiment 1, n = 6; experiment 2, n = 5; experiment 3, n = 6) ovulated 1 to 6 days after PGF2alpha, but this did not affect the emergence of ensuing follicular waves (experiments 1 and 2). These ovulations, confirmed by laparotomy and histological examinations of the ovaries (experiment 3), were not preceded by an increase in LH/FSH secretion and did not result in corpora lutea, as evidenced by transrectal ultrasonography and RIA of serum @entity1 (experiments 1 and 2). Following the removal of MAP sponges, the mean ovulation rate was 3.1 +/- 0.4 in treated ewes and 2.0 +/- 0.3 in control ewes (experiment 1; P < 0.05). In experiments 1 and 2, the ovulation rate after treatment (3.1 +/- 0.4 and 2.8 +/- 0.4) was also greater than the pretreatment rate (1.9 +/- 0.3 and 1.9 +/- 0.1, respectively). Ovulations of follicles from two consecutive waves before ovulation were seen in five treated but only in two control ewes (experiment 1), and in seven ewes in experiment 2. There were no significant differences between the MAP-treated and control ewes in mean daily serum concentrations of FSH and @entity0 , and no differences in the parameters of LH/FSH secretion, based on frequent blood sampling. Treatment of nonprolific Western white-faced ewes with PGF2alpha and MAP at midcycle changed follicular dynamics and increased ovulation rate by approximately 50%. These effects of MAP, in the absence of luteal @entity1 , may not be mediated by changes in gonadotropin secretion.

title: Effects of a 6-day treatment with XXXX after @entity2 alpha-induced luteolysis at midcycle on antral follicular development and ovulation rate in nonprolific Western white-faced ewes.

answer: @entity3


abstract: @entity4 ( @entity4 ) with assisted mechanical thrombolysis is now considered as the standard of medical care for @entity3 ( @entity3 ). The study was conducted to describe the immediate and long-term (6 months) safety and effectiveness of @entity4 in @entity0 with lower limb @entity3 compared with the routine anticoagulation alone. All 12 to 85 years old @entity0 with recent (0-8 weeks) @entity3 were included. In @entity4 group, @entity1 was aspirated mechanically and streptokinase (STK) was given along with unfractionated heparin (UFH). After 6 months, deep venous patency and @entity5 ( @entity5 ) was assessed by using duplex ultrasound and Villalta scale, respectively. Among 51 @entity0 with completed data, 25 @entity0 were allocated additional @entity4 given for a mean duration of 108        32 hours and 26 @entity0 were allocated standard treatment alone. Grade III (complete) lysis was achieved in 37% @entity0 and grade II (50-90%) lysis in 63% of @entity0 . @entity0 with partial lysis underwent percutaneous transluminal angioplasty and/or venous stenting. After 6 months, iliofemoral patency was found in 20 (80%) in the @entity4 group versus 7 (23%) in anticoagulation alone group (p   <   0.01). @entity5 was seen in 5 (20%) in the @entity4 group versus 19 (77%) in anticoagulation alone group (p   <   0.01). We conclude that @entity4 and conventional manual aspiration thrombectomy are an effective treatment for lower extremity @entity3 . STK infusion can be safely given up to 6 days. As addition of UFH can cause @entity2 , so daily monitoring of complete blood counts is needed during @entity4 .

title: Catheter-Directed Thrombolysis Along with Mechanical Thromboaspiration versus Anticoagulation Alone in the Management of Lower Limb XXXX -A Comparative Study.

answer: @entity3


abstract: The gingiva of @entity0 molars was studied at the light microscope level using @entity4 as fixative, Cuprolinic Blue for visualizing polyanionic glycosaminoglycans and the autometallographic technique for enhancing the @entity2 signal of the cationic dye. The polyanions were located inside the epithelial cells in the junctional epithelium, whereas a network located along either the plasma membrane or the intercellular spaces, or both, of the gingival oral epithelium and sulcular oral epithelium was evident with autometallography. In these cases, positive staining was limited to the basal and spinous layers, the granular and keratinized layers being unstained. With the transmission electron microscope, electron-dense aggregates were seen in the @entity3 propria, in the basement membrane and along the plasma membrane of the keratinocytes of the basal and spinous layers of the @entity5 . In the junctional epithelium, Cuprolinic Blue-positive granules, 25 nm in diameter, were seen in the cytoplasm. Together with some vesicles containing electron-dense material, they may account for the staining process noted after autometallography. When the ultra-thin sections were digested with @entity1 testicular hyaluronidase, the staining was abolished. This indicates that glycosaminoglycans were primarily responsible for the staining pattern visualized with these methods. In the junctional epithelium, the cytosolic location of the 25 nm granules reflects either transcellular transfer between the plasma membrane and the nucleus or accumulation of glycosaminoglycans in this group of keratinocytes. The glycoconjugates located inside vesicles or vacuoles are related to endocytosis and lysosomal degradation. Interstitial glycosaminoglycans seen in the two types of oral epithelium may play a role in the diffusion of water and nutriments.

title: Cuprolinic blue visualization of cytosolic and membrane-associated glycosaminoglycans in the @entity0 junctional epithelium and XXXX .

answer: @entity3


abstract: The gingiva of @entity0 molars was studied at the light microscope level using @entity4 as fixative, Cuprolinic Blue for visualizing polyanionic glycosaminoglycans and the autometallographic technique for enhancing the @entity2 signal of the cationic dye. The polyanions were located inside the epithelial cells in the junctional epithelium, whereas a network located along either the plasma membrane or the intercellular spaces, or both, of the gingival oral epithelium and sulcular oral epithelium was evident with autometallography. In these cases, positive staining was limited to the basal and spinous layers, the granular and keratinized layers being unstained. With the transmission electron microscope, electron-dense aggregates were seen in the @entity3 propria, in the basement membrane and along the plasma membrane of the keratinocytes of the basal and spinous layers of the @entity5 . In the junctional epithelium, Cuprolinic Blue-positive granules, 25 nm in diameter, were seen in the cytoplasm. Together with some vesicles containing electron-dense material, they may account for the staining process noted after autometallography. When the ultra-thin sections were digested with @entity1 testicular hyaluronidase, the staining was abolished. This indicates that glycosaminoglycans were primarily responsible for the staining pattern visualized with these methods. In the junctional epithelium, the cytosolic location of the 25 nm granules reflects either transcellular transfer between the plasma membrane and the nucleus or accumulation of glycosaminoglycans in this group of keratinocytes. The glycoconjugates located inside vesicles or vacuoles are related to endocytosis and lysosomal degradation. Interstitial glycosaminoglycans seen in the two types of oral epithelium may play a role in the diffusion of water and nutriments.

title: Cuprolinic blue visualization of cytosolic and membrane-associated glycosaminoglycans in the XXXX junctional epithelium and @entity3 .

answer: @entity0


abstract: @entity2 is a common cause of morbidity in @entity5 (HbSS): approximately 10% of @entity0 have a clinical @entity1 before 20 years of age, and another 22% have silent @entity3 on magnetic resonance imaging. The phenotypic variation among @entity0 with HbSS suggests a role for modifier genes and/or environmental influences. To assess the familial component of clinical @entity1 in HbSS, we estimated the prevalence of clinical @entity1 among all @entity0 and among HbSS sibling pairs at 9 pediatric centers. The sample included 3425 @entity0 with @entity5 who were younger than 21 years, including 2353 @entity0 with HbSS. The @entity1 prevalence was 4.9% for all genotypes; 7.1% for @entity0 with HbSS; 1.1% for @entity0 with @entity4 ; 0.6% for @entity0 with @entity4 ; and 0% for @entity0 with HbSC. In 207 sibships, more than 1 @entity0 had HbSS. There were 42 sibships in which at least 1 sibling had a @entity1 , and in 10 of the 42, 2 siblings had a @entity1 . A permutation test indicated that the number of families in which 2 @entity0 had @entity1 was larger than the number expected if @entity1 were randomly distributed among @entity0 in sibships (P =.0012). There was no difference in @entity1 prevalence based on sex, nor was the mean age at @entity1 presentation significantly different between singletons and sibships with @entity1 . We conclude that there is a familial predisposition to @entity1 in HbSS. Attempts to identify genetic modifiers should be initiated with family-based studies.

title: XXXX risk in siblings with @entity5 .

answer: @entity1


abstract: @entity2 is a common cause of morbidity in @entity5 (HbSS): approximately 10% of @entity0 have a clinical @entity1 before 20 years of age, and another 22% have silent @entity3 on magnetic resonance imaging. The phenotypic variation among @entity0 with HbSS suggests a role for modifier genes and/or environmental influences. To assess the familial component of clinical @entity1 in HbSS, we estimated the prevalence of clinical @entity1 among all @entity0 and among HbSS sibling pairs at 9 pediatric centers. The sample included 3425 @entity0 with @entity5 who were younger than 21 years, including 2353 @entity0 with HbSS. The @entity1 prevalence was 4.9% for all genotypes; 7.1% for @entity0 with HbSS; 1.1% for @entity0 with @entity4 ; 0.6% for @entity0 with @entity4 ; and 0% for @entity0 with HbSC. In 207 sibships, more than 1 @entity0 had HbSS. There were 42 sibships in which at least 1 sibling had a @entity1 , and in 10 of the 42, 2 siblings had a @entity1 . A permutation test indicated that the number of families in which 2 @entity0 had @entity1 was larger than the number expected if @entity1 were randomly distributed among @entity0 in sibships (P =.0012). There was no difference in @entity1 prevalence based on sex, nor was the mean age at @entity1 presentation significantly different between singletons and sibships with @entity1 . We conclude that there is a familial predisposition to @entity1 in HbSS. Attempts to identify genetic modifiers should be initiated with family-based studies.

title: @entity1 risk in siblings with XXXX .

answer: @entity5